The U.S. pharmaceutical supply chain is facing mounting pressure as active medication shortages climbed to 227 in the second quarter of 2026, up from 214 in the third quarter of 2025. According to data from the American Society of Health-System Pharmacists (ASHP), these shortages increasingly involve sole-source products and critical diagnostic tools, signaling a systemic challenge for healthcare providers and patients alike.
Drivers of the Rising Medication Shortage Crisis
The upward trend in drug availability gaps is fueled by a reliance on limited manufacturing sources. The ASHP reports that 48% of new shortages recorded in 2026 involve sole-source products—medications produced by only one manufacturer.
Did you know?
Contrast agents, which are essential for diagnostic procedures like CT scans and MRIs, account for 10% of all new drug shortages in 2026. These agents are vital for life-saving medical imaging, making their scarcity a significant hurdle for hospital operations.
Clinical Development Setbacks and Pipeline Shifts
Beyond supply chain constraints, the pharmaceutical industry is navigating difficult decisions regarding pipeline investments. GSK recently announced it is abandoning the development of camlipixant, a P2X3 antagonist intended to treat refractory chronic cough. This move comes just three years after the company acquired Bellus Health, the drug’s developer, in a deal valued at approximately $2 billion.
According to Pharmaphorum, the decision follows Phase 3 clinical trial results which indicated that the drug’s efficacy was unlikely to meaningfully transform patient care. This failure represents a broader trend within the P2X3 antagonist class, where multiple candidates have struggled to meet clinical benchmarks. For GSK, the termination of the camlipixant program is part of a larger strategy to streamline its late-stage pipeline, particularly as the firm prepares to manage revenue losses from patent expirations anticipated to begin in 2028.
Strategic Outlook for Pharmaceutical Manufacturers
Frequently Asked Questions
- What is the primary cause of current medication shortages?
According to the ASHP, the reliance on sole-source manufacturing is a major factor, accounting for nearly half of all new shortages. - Why did GSK stop developing camlipixant?
GSK abandoned the drug after Phase 3 trial data showed limited efficacy that would not provide a significant improvement in patient care. - Are controlled substances affected by shortages?
Yes, 16% of the active medication shortages identified in the second quarter of 2026 involve controlled substances.
Stay informed on the latest developments in the pharmaceutical industry. Subscribe to our newsletter for weekly updates on supply chain trends and clinical trial outcomes.
Worth a look